In vivo recombinant interleukin 2 administration enhances survival against a lethal challenge with Toxoplasma gondii.
In vivo recombinant interleukin 2 administration enhances survival against a lethal challenge with Toxoplasma gondii.
复制标题
DOI：
10.4049/jimmunol.135.6.4160
复制
发表时间：
1985-12
影响因子：
4.4
通讯作者：
S. Sharma;J. M. Hofflin;J. Remington
中科院分区：
文献类型：
--
作者：
S. Sharma;J. M. Hofflin;J. Remington
重组白细胞介素2（rIL 2）的管理导致显着（P <0.01），在弓形虫感染的小鼠死亡率下降剂量，杀死100%的未处理的小鼠。用rIL 2处理的小鼠脑中囊肿的数量显著减少（小于0.005）。由rIL 2提供的保护不能与增加的抗体合成相关，也不能通过治疗小鼠中增加的巨噬细胞杀伤来解释。与弓形虫感染或rIL 2治疗的小鼠相比，弓形虫感染后用rIL 2治疗的小鼠表现出增加的自然杀伤（NK）细胞活性。rIL 2不能逆转T细胞毒小鼠淋巴细胞对刀豆球蛋白A和脂多糖抑制的增殖反应。刚地这些结果提示rIL-2对细胞内寄生虫具有明显的保护作用。
Administration of recombinant interleukin 2 (rIL 2) resulted in a significant (p less than 0.01) decrease in mortality in mice infected with a dose of Toxoplasma gondii that killed 100% of untreated mice. Mice treated with rIL 2 had a significantly (less than 0.005) lower numbers of cysts in the brains. The protection afforded by rIL 2 could not be correlated with increased antibody synthesis or be explained by increased macrophage killing in the treated mice. Mice treated with rIL 2 after Toxoplasma infection demonstrated increased natural killer (NK) cell activity compared with either Toxoplasma-infected or rIL 2-treated mice. rIL 2 failed to reverse the suppressed proliferative response of lymphocytes to concanavalin A and lipopolysaccharide in mice acutely infected with a virulent strain of T. gondii. These results reveal that rIL 2 may have a remarkably protective effect against intracellular parasites.